

GAMMACAN INTERNATIONAL INC
Form 10QSB
August 09, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2006

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _____ to _____

Commission file number: 0-32835

GAMMACAN INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

33-0956433

(State or other jurisdiction of (IRS Employer Identification
incorporation or organization) No.)

Kiryat Ono Mall

Azorim Center A

39 Jerusalem st.,

55423 Kiryat Ono, Israel

(Address of principal executive offices)

972 3 7382616

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the registrant's classes of common equity, as of the latest practicable date: 28,453,732 shares issued and outstanding as of August 9, 2006.

GAMMACAN INTERNATIONAL, INC.**FORM 10-QSB****TABLE OF CONTENTS**

	Page No.
PART I	
Item 1. Financial Statements	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation	13
Item 3. Controls And Procedures	19
PART II	
Item 1. Legal Proceedings	20
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3. Defaults Upon Senior Securities	20
Item 4. Submission of Matters to a Vote of Security Holders	20
Item 5. Other Information	20
Item 6. Exhibits	22

Forward Looking Statements

This Form 10-QSB includes a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Those statements include statements regarding the intent, belief or current expectations of Gammacan and members of its management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to Management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. Gammacan believes that its assumptions are based upon reasonable data derived from and known about its business and operations and the business and operations of Gammacan. No assurances are made that actual results of operations or the results of GammaCan's future activities will not differ materially from its assumptions.

ITEM 1. - FINANCIAL STATEMENTS

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)
INTERIM FINANCIAL STATEMENTS
AS OF JUNE 30, 2006

TABLE OF CONTENTS

	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:	
Balance sheets	2
Statements of operations	3
Statements of changes in stockholders' equity	4
Statements of cash flows	5
Notes to financial statements	6-12

GAMMACAN INTERNATIONAL INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS

(US \$, except share data)

	June 30, 2006 (Unaudited)	September 30, 2005 (Audited)
Assets		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 949,230	\$ 713,342
Prepaid expenses	21,551	6,474
Other	16,793	22,029
T o t a l current assets	987,574	741,845
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT		
	15,036	7,528
LONG TERM DEPOSITS	22,210	5,145
PROPERTY AND EQUIPMENT, NET	17,422	10,269
T o t a l assets	\$ 1,042,242	\$ 764,787
<u>Liabilities and stockholders' equity</u>		
CURRENT LIABILITIES:		
Accounts payable	\$ 278,738	\$ 159,379
Payroll and related accruals	48,373	14,655
T o t a l current liabilities	327,111	174,034
LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT	24,722	13,725
STOCKHOLDERS' EQUITY:		
Preferred stock, \$ 0.0001 par value (20,000,000 shares authorized; none issued and outstanding)		
Common stock, \$ 0.0001 par value (100,000,000 authorized shares; 28,453,732 and 26,231,510 shares issued and outstanding as of June 30, 2006 and September 30, 2005, respectively)	2,845	2,622
Additional paid-in capital	3,021,021	1,767,601
Warrants	925,793	519,423
Deficit accumulated during the development stage	(3,259,250)	(1,712,618)
T o t a l stockholders' equity	690,409	577,028
T o t a l liabilities and stockholders' equity	\$ 1,042,242	\$ 764,787

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(US \$, except share data)

	Nine months ended June 30		Three months ended June 30		Period from October 6, 1998* through June 30, 2006
	2006 (Unaudited)	2005 (Unaudited)	2006 (Unaudited)	2005 (Unaudited)	(Unaudited)
RESEARCH AND DEVELOPMENT COSTS	\$ 719,153	\$ 299,985	\$ 119,610	\$ 184,987	\$ 1,432,073
GENERAL AND ADMINISTRATIVE EXPENSES	853,591	508,075	398,403	160,194	1,879,232
FINANCIAL INCOME	(36,203)	(14,618)	(12,416)	(6,652)	(56,906)
FINANCIAL EXPENSES	10,091	3,521	3,392	829	17,226
	1,546,632	796,963	508,989	399,358	3,271,625
MINORITY INTERESTS IN LOSSES OF SUBSIDIARY	-	-	-	-	(12,375)
NET LOSS FOR THE PERIOD	\$ (1,546,632)	\$ (796,963)	\$ (508,989)	\$ (399,358)	\$ (3,259,250)
BASIC AND DILUTED LOSS PER 1,000 COMMON SHARES	\$ (55.40)	\$ (30.59)	\$ (17.89)	\$ (12.94)	
WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON SHARE	27,918,176	26,055,177	28,453,732	26,231,510	

* Incorporation date, see note 1a.

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC. AND SUBSIDIARY
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(US \$, except share data)

	Common Stock	Common Stock Amount	Warrants	Additional paid-in capital	Deficit accumulated during development stage	Total
Beginning balance	-	-	-	-	-	-
Stock issued for cash on October 6, 1998	1,650,000	165		(155)		10
Stock issued for cash on October 9, 1998	2,722,500	272		(107)		165
Stock issued for cash on October 10, 1998	198,000	20		100		120
Stock issued for services on December 1, 1998	9,900,000	990		2,010		3,000
Stock issued for cash on April 7, 1999	561,000	56		284		340
Net loss					(3,444)	(3,444)
Balance at September 30, 1999 (audited)	15,031,500	1,503		2,132	(3,444)	191
Stock issued for cash on September 30, 2000	41,250,000	4,125		875		5,000
Balance at September 30, 2000 (audited)	56,281,500	5,628		3,007	(3,444)	5,191
Net loss					(3,108)	(3,108)
Balance at September 30, 2001 (audited)	56,281,500	5,628		3,007	(6,552)	2,083
Net loss					(4,231)	(4,231)
Balance at September 30, 2002 (audited)	56,281,500	5,628		3,007	(10,783)	(2,148)
Contributed capital				7,025		7,025
Net loss					(4,857)	(4,857)
Balance at September 30, 2003 (audited)	56,281,500	5,628		10,032	(15,640)	20
Cancellation of shares at June 8, 2004	(32,284,988)	(3,228)		3,228		
Stock based compensation				62,600		62,600
Common stock and warrants issued for cash on August 13, 2004	1,224,998	122	139,494	779,134		918,750
Gain on issuance of subsidiary						

Stock on August 17, 2004 to third party				86,625		86,625
Net loss					(498,446)	(498,446)
Balance at September 30, 2004 (audited)	25,221,510	2,522	139,494	941,619	(514,086)	569,549
Common stock and warrants issued for cash on November 11, 2004	978,000	97	367,892	766,630		1,134,619
Common stock and warrants issued for cash on January 25, 2005	32,000	3	12,037	24,760		36,800
Issuance of warrants to Consultants'				34,592		34,592
Net loss					(1,198,532)	(1,198,532)
Balance at September 30, 2005 (audited)	26,231,510	2,622	519,423	1,767,601	(1,712,618)	577,028
Common stock and warrants issued for cash on October 31, 2005	666,666	67	82,784	367,149		450,000
Common stock and warrants issued for cash on December 20, 2005	1,555,556	156	323,586	776,258		1,100,000
Benefit component in employees and consultants stock option plan				110,013		110,013
Net loss					(1,546,632)	(1,546,632)
Balance at June 30, 2006 (unaudited)	28,453,732 \$	2,845 \$	925,793 \$	3,021,021 \$	(3,259,250) \$	690,409

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC. AND SUBSIDIARY
(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(US \$)

	Nine months ended June 30,		Period from October 6, 1998* to June 30, 2006
	2006	2005	
	Unaudited	Unaudited	Unaudited
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net loss	\$ (1,546,632)	\$ (796,963)	\$ (3,259,250)
Adjustments required to reconcile net loss to net cash used in operating activities:			
Income and expenses not involving cash flows:			
Depreciation	2,729	1,691	5,322
Common stock issued for services	-	-	3,000
Minority interests in losses of a subsidiary	-	-	(12,375)
Write off of in process research and development	-	-	100,000
Benefit component in employees and consultants stock option plan	110,013	18,653	207,205
Changes in operating assets and liabilities:			
Increase in prepaid expenses	(15,077)	(9,678)	(21,551)
Decrease (increase) in other current assets	5,236	(23,153)	(16,793)
Increase (decrease) in current liabilities	153,077	(59,276)	326,111
Increase in liability for employee rights upon retirement	10,997	-	24,722
Net cash used in operating activities	(1,279,657)	(868,726)	(2,643,609)
CASH FLOWS FROM INVESTING ACTIVITIES -			
Increase in long term deposits	(17,065)	-	(22,210)
Funds in respect of employee rights upon retirement	(7,508)	-	(15,036)
Purchase of property and equipment	(9,882)	(7,512)	(22,744)
Net cash used in investment activities	(34,455)	(7,512)	(59,990)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Contribution to additional paid in capital			12,319
Issuance of common stock and warrants	1,550,000	1,171,419	3,640,510
Net cash provided by financing activities	1,550,000	1,171,419	3,652,829
INCREASE IN CASH AND CASH EQUIVALENTS	235,888	295,181	949,230
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	713,342	705,868	
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 949,230	\$ 1,001,049	\$ 949,230

* Incorporation date, see note 1a.

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

a.

General:

GammaCan International Inc. (A Development Stage Company; "the Company") was incorporated on October 6, 1998, under the laws of the State of Delaware, under the name of San Jose International, Inc. The Company has no significant revenues and no material operations and in accordance with Statement of financial Accounting Standard ("SFAS") No. 7 "Accounting and Reporting by Development Stage enterprises", the Company is considered a development stage company.

On August 19, 2004, the name of the company was changed from "San Jose International, Inc." into "GammaCan International, Inc."

At this point in the development stage, the company's focus is to demonstrate efficacy of IVIg cancer immunotherapy in human clinical trials. In July 2005, the company commenced Phase 2 clinical trials in humans to demonstrate clinical efficacy of IVIg immunotherapy in three major cancers: colon, prostate and melanoma. These Phase 2 clinical trials are being conducted at three medical centers in Israel and results are anticipated during 2007. The Phase 2 clinical trial is due to be completed by the beginning of 2007.

The Company is in the process of applying for an IND with the US FDA for VitiGam, The Company's second generation IgG product and first-in-class anti-cancer immunotherapy. VitiGam is slated to enter the clinic under a US IND in the near future. VitiGam is designed to target metastatic melanoma patients with Stage III and IV melanoma.

The financial statements have been prepared assuming the Company will continue as a going concern. See note 3.

b.

Accounting principles

The accompanying unaudited financial statements of the Company and the subsidiary GammaCan Ltd. ("the Subsidiary") have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-QSB and Item 310 of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended June 30, 2006, are not necessarily indicative of the results that may be expected for the year ended September 30, 2006. For further information, refer to the financial statements and footnotes thereto included in the consolidated annual report on Form 10-KSB for the year ended September 30, 2005.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

c. Use of estimates in the preparation of financial statements

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statement date and the reported expenses during the reporting periods. Actual results could differ from those estimates.

d. Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiary GammaCan Ltd. All material intercompany transactions and balances have been eliminated in consolidation.

e. Cash equivalents

The company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.

f. Loss per share

Basic and diluted net losses per common share are presented in accordance with FAS No. 128 "Earning per share" ("FAS128"), for all periods presented. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stocks options and warrants excluded from the calculations of diluted net loss was 5,967,775 for the nine months ended June 30, 2006 (2,484,998 for the nine months ended June 30, 2005).

g. Stock based compensation

The Company accounts for employee stock based compensation in accordance with Accounting Principles Board Opinion No. 25 "Accounting for Stock Issued to Employees" ("APB 25") and related interpretations. In accordance with FAS 123 - "Accounting for Stock-Based Compensation" ("FAS 123"), the Company discloses pro forma data assuming the Company had accounted for employee stock option grants using the fair value-based method defined in FAS 123.

As to services from consultants, the Company applies EITF 96-18 "Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services".

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

The following table illustrates the pro - forma effect on net loss and loss per common share assuming the Company had applied the fair value recognition provisions of FAS 123 to its stock-based employee compensation:

	Nine months ended June 30,	
	2006	2005
Net loss as reported	\$ (1,546,632)	\$ (796,963)
Deduct: Stock based employee compensation expense included in net loss as reported	79,010	
Add: pro forma stock based employee compensation expense determined under fair value method for all awards, net of related tax effects	(573,927)	(89,638)
Recognize the reversal of the pro forma stock based employee compensation expense determined under fair value method due to forfeiture of awards granted to employees	79,676	118,190
Pro forma net loss	\$ (1,961,873)	\$ (768,411)
Net loss per 1,000 common shares:		
Basic and diluted loss per 1,000 shares - as reported	\$ (55.40)	\$ (30.59)
Basic and diluted loss per 1,000 shares - pro forma	\$ (70.27)	\$ (29.49)

h. Reclassifications

Certain figures in respect of prior years have been reclassified to conform to the current year presentation.

i. Recently issued accounting pronouncements

In February 2006, the FASB issued FAS 155, accounting for certain Hybrid Financial Instruments, an amendment of FASB statements No.133 and 140. This statement permits fair value measurement for any hybrid financial instrument that contains an embedded derivative that otherwise would require bifurcation. This statement is effective for all financial instruments acquired or issued after the beginning of an entity's first fiscal year that begins after September 15, 2006. Earlier adoption is permitted as of the beginning of an entity's fiscal year, provided that no interim period financial statements have been issued for the financial year. In the Company's opinion, implementation of this standard is not expected to have a material effect on its financial statements in future periods.

In March 2006 the Financial Accounting Standards Board (the "FASB") issued Statement of Financial Reporting No. 156 ("FAS 156"). This Statement amends FASB Statement No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities, with respect to the accounting for separately recognized servicing assets and servicing liabilities, and is effective for financial periods beginning after September 15, 2006. Since the Company does not currently engage in transfers of financial fixed assets, the company does not anticipate that the adoption of this statement will have a material impact on its financial statements.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

In July 2006, the FASB issued FASB Interpretation (FIN) No. 48 Accounting for Uncertainty in Income Taxes an interpretation of FASB Statement 109. FIN 48 prescribes a comprehensive model for recognizing, measuring, presenting and disclosing in the financial statements tax positions taken or expected to be taken on a tax return, including a decision whether to file or not to file in a particular jurisdiction. FIN 48 is effective for fiscal years beginning after December 15, 2006. If there are changes in net assets as a result of application of FIN 48 these will be accounted for as an adjustment to retained earnings. In the Company's opinion, implementation of this standard is not expected to have a material effect on its financial statements in future periods.

NOTE 2 - LONG TERM DEPOSITS

Amount represents deposits in respect of lease agreements for the company's office facilities and vehicles used by its employee

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (October 6, 1998) through June 30, 2006 of \$3,259,250. Presently, the company does not have sufficient cash resources to meet its requirements in the twelve months following July 1, 2006. These factors raise substantial doubt about the company's ability to continue as a going concern. The company's management estimates that it will be able to finance the company's activities through future fund raising.

These financial statements do not include any adjustments that may be necessary should the company be unable to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability.

NOTE 4 - STOCK TRANSACTIONS:

- a. On October 31, 2005, the company entered into subscription agreement for the sale of 666,666 units at a purchase price of \$0.75 per unit for a total consideration of \$500,000. Each unit comprising one share of the Company's common stock and one common share purchase warrant exercisable for three years. Every 2 warrants can be exercisable to one common Share at a price of \$1.00 per Share.

In connection with the subscription agreement the company paid \$50,000 cash fee to a third party which assisted in securing the agreement, as well as issued 66,666 units, each comprising of one common share purchase warrant exercisable for three years. Every warrant can be exercisable to one common Share at a price of \$1.50 per Share.

The value allocated to all warrants estimated by using the Black Scholes option-pricing model is \$82,784. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 80%; risk-free interest rates of 4.4%; and expected lives of 3 years.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 4 - STOCK TRANSACTIONS (continued):

b. On October 6, 2005, 350,000 options were granted under the Stock Option Plan. The exercise price has been determined at \$0.93 per common share which was equivalent to 90% of the traded market price on the date of grant. Compensation costs calculated in accordance with APB 25 totaled \$35,000.

As to the exercise terms of the options - see note j below.

The fair value of the above options on the date of grant estimated by using Black Scholes option-pricing model is \$283,757. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 80%; risk-free interest rates of 4.5%; and expected lives of 7.59 years.

c. On October 20, 2005, 30,000 options were granted under the Stock Option Plan. The exercise price has been determined at \$1.35 per common share which was equivalent to the traded market price on the date of grant.

The options may be exercised after vesting and in accordance with the following:

1. 25% of the options - On the first anniversary commencing the grant date
2. 75% of the options - On the last day of each of the 36 months following the first anniversary of the grant date, the options shall vest in equal monthly installments.

The fair value of the above options on the date of grant estimated by using Black Scholes option-pricing model is \$32,637. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 85%; risk-free interest rates of 4.5%; and expected lives of 7.85 years.

d. On December 20, 2005, the company entered into subscription agreement for the sale of 1,333,334 units at a purchase price of \$0.75 per unit for a total consideration of \$1,000,000. Each unit comprising one share of the Company's common stock and one common share purchase warrant exercisable for three years. Every warrant can be exercisable to one Share at a price of \$1.20 per common Share.

In connection with the subscription agreement the company paid \$100,000 cash fee to third parties who assisted in securing the agreement, as well as issued 133,332 units, each comprising of one common share purchase warrant exercisable for three years. 66,666 warrants can be exercisable to 66,666 common Shares at a price of \$1.25 per Share, and 66,666 warrants can be exercisable to 66,666 common Shares at a price of \$1.50 per Share.

The value allocated to all warrants estimated by using the Black Scholes option-pricing model is \$294,443. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 81%; risk-free interest rates of 4.4%; and expected lives of 3 years.

e. On December 20, 2005, the company entered into subscription agreement for the sale of 222,222 units at a purchase price of \$0.90 per unit for a total consideration of \$200,000. Each unit comprising one share of the Company's common stock and one common share purchase warrant exercisable for three years. Every 2 warrants can be exercisable to one common Share at a price of \$1.15 per Share.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 4 - STOCK TRANSACTIONS (continued):

The value allocated to all warrants estimated by using the Black Scholes option-pricing model is \$29,143. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 81%; risk-free interest rates of 4.4%; and expected lives of 3 years.

f. On December 21, 2005, 250,000 options were granted under the Stock Option Plan. The exercise price has been determined at \$1.34 per common share which was equivalent to the traded market price on the date of grant. As to the exercise terms of the options - see exercise terms in note 3c.

The fair Value of the above mentioned options on the date of the grant estimated by using the Black Scholes option-pricing model is \$269,449. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 85%; risk-free interest rates of 4.5%; and expected lives of 7.85 years.

g. On January 12, 2006, 50,000 options were granted under the Stock Option Plan. The exercise price has been determined at \$1.10 per common share which was equivalent to the traded market price on the date of grant. As to the exercise terms of the options - see note k below.

The fair Value of the above mentioned options on the date of the grant estimated by using the Black Scholes option-pricing model is \$44,165. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 85%; risk-free interest rates of 4.5%; and expected lives of 7.85 years.

h. On March 15, 2006, 50,000 options were granted under the Stock Option Plan. The exercise price has been determined at \$1.37 per common share which was equivalent to the traded market price on the date of grant. As to the exercise terms of the options - see exercise terms in note c above.

The fair Value of the above mentioned options on the date of grant estimated by using the Black Scholes option-pricing model is \$54,712. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 84%; risk-free interest rates of 4.5%; and expected lives of 7.85 years.

i. On April 17, 2006, 1,400,000 stock options were granted to the new CEO under the Stock Option Plan. The exercise price has been determined at \$1.29 per common share which was equivalent to 90% of the average closing price of the common Stock of the company on the 30 days immediately preceding the date of grant. Compensation costs calculated in accordance with APB 25 totaled \$434,000. As to the exercise terms of the options - see exercise terms in note c above.

The fair Value of the above mentioned options on the date of grant estimated by using the Black Scholes option-pricing model is \$1,832,296. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 83%; risk-free interest rates of 4.5%; and expected lives of 7.85 years.

NOTE 4 - STOCK TRANSACTIONS (continued):

j. On May 2, 2006 the company amended the vesting of the 350,000 options granted on October 6, 2005. The options may be exercised after vesting and in accordance with the following:

1. 25% of the options - On the first anniversary commencing the grant date
2. 75% of the options - On the last day of each of the 36 months following the first anniversary of the grant date, the options shall vest in equal monthly installments.

k. On May 2, 2006 the company amended the vesting of the 50,000 options granted on January 12, 2006.

1. 25% of the options - On October 1, 2006.
2. 75% of the options - On the last day of each of the 36 months following October 1, 2006, the options shall vest in equal monthly installments.

l. On May 4, 2006, 500,000 (100,000 for each of its five board members) options were granted under the Stock Option Plan. The exercise price has been determined at \$1.29 per common share (see also note i above regarding the determined exercise price). Compensation costs calculated in accordance with APB 25 totaled \$105,000. As to the exercise terms of the options - see exercise terms in note c above.

The fair Value of the above mentioned options on the date of grant estimated by using the Black Scholes option-pricing model is \$605,909. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 83%; risk-free interest rates of 4.5%; and expected lives of 7.85 years.

NOTE 5 - RELATED PARTIES - TRANSACTIONS:

a. On April 15, 2005, the CEO of the subsidiary who also served as the Acting CEO of the company had resigned from its position as the acting CEO of the company, and will continue as the CEO of the subsidiary.

b. On April 16, 2006, the Company entered into an employment agreement (the "Agreement") with its new CEO pursuant to which the new CEO will serve as CEO of the Company, effective April 15, 2006. Mr. Schnegelsberg shall receive an annual salary of \$200,000 and an annual bonus of up to \$200,000 upon achieving certain objectives. Pursuant to a separate agreement between the company and the new CEO, the company agreed to indemnify the new CEO for substantially all liabilities he may incur as a result of his employment by or service to the company.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

As used in this current report, the terms "we", "us", "our", and "Gammacan" mean Gammacan International, Inc. and our subsidiary, Gammacan, Ltd., unless otherwise indicated.

All dollar amounts refer to US dollars unless otherwise indicated.

We currently have no revenue from operations, we are in a start-up phase with our existing assets and we have no significant assets, tangible or intangible. There can be no assurance that we will generate revenues in the future, or that we will be able to operate profitably in the future, if at all. We have incurred net losses in each fiscal year since inception of our operations.

Our initial focus over the next several years is to demonstrate efficacy of IGg cancer immunotherapy in human clinical trials. Efficacy is the ability of a drug or other treatment to produce the desired result when taken by its intended users. If ultimately proven to be successful, and there can be no assurance that it will be, we could be well-positioned to enter a licensing agreement with a major pharmaceutical partner for commercial market development and sales.

Since July 2005, we have been conducting a Phase 2 clinical trial in humans to demonstrate clinical efficacy of IGg immunotherapy in three major cancers: colon, prostate and melanoma. To date, 31 patients have been enrolled, out of which 27 have actually received the IGg treatment. This phase 2 clinical trial is being conducted at three medical centers in Israel and results will likely be available during 2007. The trial is due to be completed by the beginning of 2007, but we will probably continue to monitor patients for a number of years after the trial in order to collect additional evidence of efficacy and potential benefits or adverse effects of the IGg treatment. If successful or promising, and at this preliminary stage there is no assurance they will be, results of these clinical trials will be used to enter into discussions with a major pharmaceutical partner and plasma based product manufacturers to work with us to potentially commercialize the IGg products. This commercialization will include pivotal, Phase 3 clinical trials in accordance with regulatory requirements. Such trials may be long-term trials and may require substantial financial resources that we do not presently possess.

We expect that it will take a number of years to receive final approval and registration of an IGg preparation for use as an anti-cancer reagent. However, the company's strategy is to collaborate with a suitable IGg manufacturer and license them the rights to use IGg as an anti-cancer agent, wherefore the company's expected revenue stream is not entirely dependent upon the registration of the IGg products.

We are in the process of applying for an IND with the US FDA for VitiGam, GammaCan's second generation IGg product and first-in-class anti-cancer immunotherapy. VitiGam is slated to enter the clinic under a US IND in the near future. VitiGam is designed to target metastatic melanoma patients with Stage III and IV melanoma.

VitiGam is an intravenous IgG mixture derived from IGg manufactured from plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that vitiligo derived IGg (VitiGam) contains anti-melanoma activities in substantially higher quantities than those found in IGg from other donors. This "enriched" vitiligo IGg (VitiGam) has potent anti-melanoma activity in both *in vitro* and *in vivo* melanoma models. Preliminary data from the ongoing, open-label Phase 2 trial of GCAN 101 ("standard" IGg) in cancer patients (melanoma, prostate and colon) further support the rationale underling the VitiGam program.

The Company intends to conduct a Phase 1/2 under a US IND to evaluate VitiGam in patients with stage III and IV melanoma. As described under the Planned Expenditure section, the estimated costs of this Phase 1/2 are substantial; the timing of initiation of the Phase 1/2 trials will be based on several major factors, including the ability of the Company to attract sufficient financing on acceptable terms.

We are also contemplating to conduct additional clinical trials to test new formulations of IGg and to test IGg immunotherapies for different cancers at different stages of disease progression with varying dosages and routes of administration. To achieve this we may elect to partner with a pharmaceutical company to conduct these further Phase 2 and Phase 3 trials, in order to attain broad-based regulatory approval.

Long Term Business Strategy

As noted previously, if IGg shows significant promise in clinical trials, we may seek a strategic commercial partner, or partners, with extensive experience in commercialization and marketing of cancer drugs and or therapeutic proteins. It is envisaged that the partner, or partners, would be responsible for ensuring regulatory approvals and registrations in a timely manner and for the penetration of our IGg immunotherapies to the market. Any such strategic partnership, or partnerships, could provide a marketing and sales infrastructure for our products as well as financial and operational support for global trials and other FDA requirements concerning future clinical development. Putative future strategic partner, or partners, could also provide capital and expertise that would enable the partnership to develop new formulations of IGg cancer immunotherapy suitable for patients at different stages of disease progression as well as IGg derivatives and to develop novel methods for the delivery for IGg based therapies.

Other Research and Development Plans

In addition to conducting early-stage clinical trials, we plan to conduct research to develop alternative delivery systems, to determine the optimal dosage for different patient groups and to investigate alternative sources of immunoglobulin other than human plasma. We plan to conduct research to isolate the fraction of IGg, which is responsible for its anti-metastatic effects and to develop a potential synthetic version of IGg. These formulations will be suitable for:

- Low-dose, preventative therapy for disease-free, high-risk individuals,
- High dosages for use in conjunction with surgery and other cancer treatments, and
- Maintenance dose for use to prevent recurrence of cancer growth.
- Others

Our plan is to patent any successful inventions resulting from our further research activities.

Other Strategic Plans

If appropriate, we will consider in-licensing and other means of obtaining access to additional compounds for our product portfolio. The aim of this is to create a well-balanced product portfolio that includes compounds at different stages of development and addressing different medical needs.

Critical accounting policies and estimates

Management's discussion and analysis of the financial condition and results of operations is based upon the consolidated financial statements, which have been prepared in accordance with accounting principals generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and judgments. We base our estimates on various factors, including historical experience that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other resources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

Going concern assumption

The financial statements have been prepared assuming the Company will continue as a going concern. Through June 30, 2006, the Company has incurred losses in an aggregate amount of \$3,259,250. Such losses have resulted from the Company's activities as a development stage company. These factors raise substantial doubt about the company's ability to continue as a going concern. We estimate that the cash reserves available on June 30, 2006 will be sufficient to cover the planned expenses through September 30, 2006. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability.

Valuation of options and warrants

We granted options to purchase common shares of our company to employees and consultants as well as issue warrants in connection with fund raising. The fair value of the options and warrants is estimated by using the Black Scholes option-pricing model, and is based on certain assumptions regarding the expected dividends, expected volatility, expected life of the options and warrant and the risk free interest rate.

Results of Operations

Nine months ended June 30, 2006 and 2005

The following table summarizes certain statement of operations data for the company for the six months period ended June 30, 2006 and 2005 (in US\$):

	Nine months ended June 30,	
	2006	2005
Research and development costs	\$ 719,153	\$ 299,985
General and administrative expenses	853,591	508,075
Financial income net	(26,112)	(11,097)
Net loss for the period	\$ 1,546,632	\$ 796,963

Research and development costs.

Research and development expenses are the costs incurred in the process of our pre-clinical trial and clinical trial.

During the nine months ended June 30, 2006 and June 30, 2005 the research and development expenses included, among other, the clinical trial and pre-clinical trial expenses, the consultants compensation, costs related to the registered patents as well as salaries and related expenses.

During the nine months ended June 30, 2006 the research and development expenses totaled \$719,153, compared to \$299,985 during the nine months ended June 30, 2005. The increase in costs is due to the conducted Phase 2 trial whereas during the nine months ended June 30, 2005 the costs were related to the pre-clinical activity.

General and administrative expenses

The general and administrative expense includes the salaries and related expenses of the company's management, consulting, legal and professional fees, traveling, business development costs as well as insurance expenses.

For the nine months ending June 30, 2006 the General and administrative expense totaled \$853,591 compared to \$508,075 for the nine months ended June 30, 2005. Costs incurred related to general and administrative in the nine months ended June 30, 2006 reflect an increase in activities as well as increased number of employees as compared to the nine months period ending June 30, 2005.

Financial income/expense, net

During the nine months ending June 30, 2006 and June 30, 2005, the company generated interest income on available cash and cash equivalents balance.

Liquidity and Capital Recourses

Financing activities

Through June 30, 2006, the Company has incurred losses in an aggregate amount of \$3,259,250. We have financed our operation from private placement of common stock. Through June 30, 2006 we raised a total of \$3,652,829, net of transaction cost, through private placements and we anticipate that additional financing will be through similar sources. Our financing activates for the nine months period ending June 30, 2006 include the following:

On October 31, 2005, the company entered into subscription agreement for the sale of 666,666 units at a purchase price of \$0.75 per unit for a total consideration of \$500,000.

On December 20, 2005, the company entered into subscription agreement for the sale of 1,333,334 units at a purchase price of \$0.75 per unit for a total consideration of \$1,000,000.

On December 20, 2005, the company entered into subscription agreement for the sale of 222,222 units at a purchase price of \$0.90 per unit for a total consideration of \$200,000.

Employee's stock options plan

On October 6, 2005 we granted options to purchase up to 350,000 common shares of our company at an exercise price of \$0.93 to Mr. Chaime Orlev.

On October 20, 2005 we granted options to purchase up to 30,000 common shares of our company at an exercise price of \$1.35 to an employee.

On December 21, 2005 we granted options to purchase up to 250,000 common shares of our company at an exercise price of \$1.34 to an employee.

On January 12, 2006 we granted options to purchase up to 50,000 common shares of our company at an exercise price of \$1.10 to an employee.

On March 15, 2006 we granted options to purchase up to 50,000 common shares of our company at an exercise price of \$1.37 to a director of the company.

On April 17, 2006 we granted options to purchase up to 1,400,000 common shares of our company at an exercise price of \$1.29 to Mr. Patrick Schnegelsberg.

On May 4, 2006 we granted options to purchase up to 100,000 common shares of our company at an exercise price of \$1.29 to each of the five members of the board for a total of 500,000 options.

Summary of financing activities

Through June 30, 2006 we raised approximately \$3.6 Million through private placements of our securities. As of June 30, 2006 the cash and cash equivalents totaled \$949,230. We anticipate that these reserves will be sufficient to fund operation through September 30, 2006. Continuation of our current operations after utilizing the mentioned reserves during the year ending September 30, 2006, is dependent upon obtaining financial support from investors until profitable results are achieved.

Planned Expenditures

The estimate expenses referenced herein are in accordance with the business plan. As the technology is still in the development stage, it can be expected that there will be changes in some budgetary items. Our planned expenditures for the next 12 months include:

Category	Amount
Research & Development	1,207,000
Business Development	211,000
General & Administrative Expenses	1,345,000
Total	2,763,000

We are planning to conduct an additional clinical trial to demonstrate clinical efficacy of VitiGam an IGg sourced from a specific population, in patients with stage III or IV melanoma. We began initial process of planning this trial during the first half of 2006. The decision to proceed past the initial process will be based on several major factors, one of which is the ability of the company to attract sufficient financing on acceptable terms. If we elect to continue this VitiGam trial past the initial process, we anticipate that our related clinical trial costs over the next 12 months would increase by approximately \$3,000,000.

Related party transactions

Mr. Yair Aloni, a director of our company, and Professor Yehuda Shoefeld, M.D., the Chief Scientist of our subsidiary, Gammacan, Ltd., are authorized signatories of ARP Biomed Ltd. for the Intellectual Property Purchase and Sale Agreement we entered into with ARP Biomed Ltd. on June 11, 2004. Mr. Aloni is the Chief Executive Officer of ARP.

On June 6, 2005, the Company and Gammacan, Ltd. appointed Vered Caplan as acting Chief Executive Officer of both companies, effective July 2, 2005. Vered Caplan will devote approximately 70% of her business time to the affairs of Gammacan, Ltd. and the Company. Vered Caplan shall receive a salary of \$6,475 per month. On April 15,

2006 Vered Caplan has resigned from her position as the acting Chief Executive Officer of the company. Vered Caplan will remain as the Chief Executive Officer of Gammacan, Ltd.

On April 16, 2006, the Company entered into an employment agreement (the "Agreement") with Patrick Schnegelsberg pursuant to which Mr. Schnegelsberg will serve as Chief Executive Officer of the Company, effective April 15, 2006. Mr. Schnegelsberg shall receive a salary of \$200,000 and an annual bonus of up to \$200,000 upon achieving certain objectives. Pursuant to a separate agreement between the Company and Mr. Schnegelsberg, the Company agreed to indemnify Mr. Schnegelsberg for substantially all liabilities he may incur as a result of his employment by or service to the Company. Mr. Schnegelsberg was granted 1,400,000 stock options of the Corporation, pursuant to the Corporation's 2004 Stock Option Plan, adopted by the Board on August 17, 2004. Options are exercisable at an exercise price of \$1.29 per share. 350,000 of the Options shall vest on the first anniversary from their date of grant, and the remaining Options shall vest in 36 equal monthly instalments thereafter

ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures. As of June 30, 2006, the Company's management carried out an evaluation, under the supervision of the Company's Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company's system of disclosure controls and procedures pursuant to the Securities and Exchange Act, Rule 13a-15(d) and 15d-15(d) under the Exchange Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective, as of the date of their evaluation, for the purposes of recording, processing, summarizing and timely reporting material information required to be disclosed in reports filed by the Company under the Securities Exchange Act of 1934.

Changes in internal controls. There were no changes in the Company's internal controls over financial reporting, that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.

PART II

ITEM 1 LEGAL PROCEEDINGS

From time to time the Company is subject to litigation incidental to its business. Such claims, if successful, could exceed applicable insurance coverage. The Company is not currently a party to any material legal proceedings.

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On October 31, 2005 the company entered into subscription agreements for the sale of 666,666 units to an offshore investor at a purchase price of \$0.75 per unit for a total consideration of \$500,000. Each unit comprising one share of the Company's common stock and one common share purchase warrant exercisable for three years for ½ (half) a share at a price of \$1.00 per Share.

On December 20, 2005 the company entered into a subscription agreement for the sale of 1,333,334 units to an accredited investor at a purchase price of \$0.75 per unit for a total consideration of \$1,000,000. Each unit comprising one share of the Company's common stock and one common share purchase warrant exercisable for three years for one share at a price of \$1.20 per share.

On December 20, 2005 the company entered into a subscription agreement for the sale of 222,222 units to an accredited investor at a purchase price of \$0.90 per unit for a total consideration of \$200,000. Each unit comprising one share of the Company's common stock and one common share purchase warrant exercisable for three years for ½ (half) a share at a price of \$1.15 per share.

For each sale of these units we relied on either the exemption from registration provided for accredited investors pursuant to Rule 506 of Regulation D, or Regulation S promulgated under the Securities Act of 1933, as amended.

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable.

ITEM 5 OTHER INFORMATION

Not applicable.

ITEM 6 EXHIBITS

31.1 - Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended

31.2 - Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended

32.1 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)

32.2 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GAMMACAN INTERNATIONAL, INC.

August 9, 2006

/s/ CHAIME ORLEV
Chaime Orlev,
Chief Financial Officer